|
|
 |
|
Viewing report
|
|
|
|
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access
Just Pharma Reports, Feb 2010, Pages: 91
A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapore’s Medicines (Orphan Drug) Exemption Order of 1991 was the first legislation anywhere to follow the US Orphan Drug Act, with the other four Asia-Pacific countries also implementing orphan-promoting measures ahead of the EU.
Rare diseases are collectively not that rare, indeed 6-10% of people will suffer from one at some point in life. Asia-Pacific contains nearly two-thirds of the world’s population, and should offer great potential to companies developing orphan drugs. But clinical need alone does not mean that adequate money for diagnosis and treatment will be made available.
The report describes the processes for obtaining orphan product designation, what can be omitted from the standard dossier to obtain marketing authorisation, and provides full details of the regulatory bodies and timelines involved. The main emphasis though is not on registration but on market access, which for products like orphan drugs that often carry premium prices, means eligibility for reimbursement or other sources of public funds.
Based on extensive research, including fieldwork in Tokyo and Seoul in November 2009 to capture detail, understanding and all the latest trends, the report includes:
- The incentives on offer to orphan drug sponsors.
- How P&R processes work specifically for orphan drugs.
- The role of HTA and risk sharing as levers to obtain reimbursement.
- Where special funding schemes operate and how to access them.
- 13 case studies on the P&R history of 12 different orphan drugs in 5 countries.
- How much patients are expected to contribute to the cost of their treatment.
- Listings of designated and approved orphan drugs.
- Comparisons between countries with orphan drug policies and those without.
- Contact details of the main rare disease patient organisations.
Learn which of the Asia-Pacific countries offers the most comprehensive programme for the management of rare disease often enjoys higher orphan drug prices than the US has the most orphan drugs on the market and reimbursed promotes the development of rare disease medical devices as well as drugs where ‘named patient’ imports are discouraged by rare disease patient representatives.
Customers who bought this item also bought
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2011 Edition
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies
Orphan Drugs: Strategic Approaches for the Industry
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
Market Access Korea - Breaking into the Developed World’s Fastest Growing Pharmaceutical Market
Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
Pharmaceutical Pricing and Reimbursement - Reference Pricing and Economic Evaluations Will Dominate Future Pricing and Reimbursement Strategies
Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2012
Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs
|
|
|
|
